Article
CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Dec 2012
Weischer Maren, Nordestgaard Børge G, Pharoah Paul, Bolla Manjeet K, Nevanlinna Heli, Van't Veer Laura J, Garcia-Closas Montserrat, Hopper John L, Hall Per, Andrulis Irene L, Devilee Peter, Fasching Peter A, Anton-Culver Hoda, Lambrechts Diether, Hooning Maartje, Cox Angela, Giles Graham G, Burwinkel Barbara, Lindblom Annika, Couch Fergus J, Mannermaa Arto, Grenaker Alnæs Grethe, John Esther M, Dörk Thilo, Flyger Henrik, Dunning Alison M, Wang Qin, Muranen Taru A, van Hien Richard, Figueroa Jonine, Southey Melissa C, Czene Kamila, Knight Julia A, Tollenaar Rob A E M, Beckmann Matthias W, Ziogas Argyrios, Christiaens Marie-Rose, Collée Johanna Margriet, Reed Malcolm W R, Severi Gianluca, Marme Frederik, Margolin Sara, Olson Janet E, Kosma Veli-Matti, Kristensen Vessela N, Miron Alexander, Bogdanova Natalia, Shah Mitul, Blomqvist Carl, Broeks Annegien, Sherman Mark, Phillips Kelly-Anne, Li Jingmei, Liu Jianjun, Glendon Gord, Seynaeve Caroline, Ekici Arif B, Leunen Karin, Kriege Mieke, Cross Simon S, Baglietto Laura, Sohn Christof, Wang Xianshu, Kataja Vesa, Børresen-Dale Anne-Lise, Meyer Andreas, Easton Douglas F, Schmidt Marjanka K, Bojesen Stig E
Abstract excerpt
PURPOSE: We tested the hypotheses that CHEK2*1100delC heterozygosity is associated with increased risk of early death, breast cancer-specific death, and risk of a second breast cancer in women with a first breast cancer. PATIENTS AND METHODS: From 22 studies participating in the Breast Cancer Association Consortium, 25,571 white women with invasive breast cancer were genotyped for CHEK2*1100delC and observed for...
Read the complete abstract on PubMed